<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>OmniSeq Page 4</title>
    <link href="https://fonts.googleapis.com/css?family=Lato&display=swap" rel="stylesheet">
     <link rel="stylesheet" type="text/css" href="{{ STATIC_PREFIX }}css/main.css">
</head>
<body>
<!--
Additional Immuno-Oncology Markers
-->
<img src="{{ STATIC_PREFIX }}IntegratedOncology.jpg" width="150" />

<img class="Omniseq_logo" src="{{ STATIC_PREFIX }}omniseqCdx_logo.png" />


<div class="Additional_Immuno_Oncology_Wrapper">
    <div class="IO_Marker"><div class="IO_Marker_Text">Additional Immuno-Oncology Markers</div> </div>
    <div><span class="Additional_Immuno_Oncology_Wrapper_Span">First generation immune checkpoint inhibitors (anti-CTLA-4 and anti-PD-1/PD-L1) target natural immune homeostasis pathways, co-opted by cancers, to drive anti-tumor immune responses. While these agents have led to unprecedented response and outcomes in patients with previously incurable metastatic disease, they are highly efficacious in only a minority of patients. Newer strategies that target additional immunomodulatory mechanisms to activate patients' anti-tumor immune responses are in development. Emerging immune targets with pre-clinical efficacy have progressed to active investigation in clinical trials. These targets include co-inhibitory and co-stimulatory markers of the innate and adaptive immune system (PMID: 28987965). Clinical trials for these therapies often do not require the presence of biomarkers, however, the proposed mechanism of action of the drugs being tested suggests tumors that over- or under-express messenger RNA (mRNA) in immune-cycle related genes are more likely to respond to immunotherapeutic strategies directed at these mechanisms of immune response and suppression.
    </span></div>
</div>
<div class="Vertical_Spacer_10"></div>

{% for io_detail in patient['additional_io_details'] %}

<div class="Additional_Immuno_Oncology_Wrapper">
    <div class="IO_Marker">
        <div class="IO_Marker_Text">{{ io_detail['marker'] }}<br/>Rank = {{ io_detail['rank'] }} ({{ io_detail['interpretation']}})</div>
    </div>
    <div>
        <span class="Additional_Immuno_Oncology_Wrapper_Span">
            {{ io_detail['description']['description'] }}
            <a href="https://www.ncbi.nlm.nih.gov/pubmed/{{io_detail['description']['pmid']|trim }}"
                                   target="_blank">(PMID:{{io_detail['description']['pmid']|trim}})</a>
        </span>
    </div>
</div>
<div class="Emerging_Header">EMERGING - Clinical Trials (Level IIC)</div>
 <div class="Therapy_Details_Wrapper">
        <div style="background-color: lightgray">Therapy</div>
        <div style="background-color: lightgray">Availability</div>
        <div style="background-color: lightgray">Efficacy</div>
{%  for trial in io_detail['trials'] %}
            <div>{{ trial['therapy'] }}</div>
            <div>{{ trial['availability'] }}</div>
            <div>{{ trial['efficacy'] }}</div>
{% endfor %}
  </div>
<div class="Vertical_Spacer_10"></div>

{% endfor %}

<div class="Vertical_Spacer_50"></div>

<div class="Footer">
     {{patient['test_id']}}&nbsp;P-20-00000-000 VERSION 1 | Report electronically signed by George Who, MD
    |{{patient['sign_out_date']}} <br>
    CLIA ID: 33D2098748 | CAP # 9405346 | OmniSeq Inc., 700 Ellicott Street, Buffalo NY 14203 | 1 (800) 781-1259
<img class="Cap_logo" src="{{ STATIC_PREFIX }}cap_logo.png" width="75" />

</div>

</body>
</html>